phase readout

NCT04221555: Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

COMPLETEDupdated 20d ago

community read0 votes

Sponsor: Asan Medical Center. Phase: PHASE2. Conditions: Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Data sources

last refreshed 11m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?